<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00251368</url>
  </required_header>
  <id_info>
    <org_study_id>94-115</org_study_id>
    <nct_id>NCT00251368</nct_id>
  </id_info>
  <brief_title>Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory Leukemia</brief_title>
  <official_title>Multicenter Study of 9-AC in Refractory Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the side effects of 9-Aminocamptothecin (9-AC) and
      to determine the best dose which should be used to treat leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  The treatment patients will receive involves a continuous infusion of 9-AC intravenously
           for a 72 hour period. Since we are unsure of the safest and most effective dose,
           successive groups of 4-7 patients will receive larger doses of this drug until the
           largest dose given safely is established.

        -  Prior to the start of therapy a bone marrow aspirate and biopsy will be taken for
           diagnostic and research purposes. A bone marrow exam will be repeated at 48 hours in
           order to determine the effects of 9-AC on leukemic cells in the bone marrow. A bone
           marrow scan will also be performed 14 days after the start of therapy to assess
           response.

        -  Frequent blood testing will be done throughout treatment, including blood samples to
           determine the levels of the 9-AC in the blood.

        -  Treatment could be stopped prematurely if any of the following occur: 1) drug causes
           severe side effects, 2) the drug does not control the leukemia, or 3) the doctors or the
           patient feel that it is no longer in the patients best interest to receive this therapy.

        -  Approximately 7 days after the conclusion of the 9-AC infusion, it is likely that the
           patient's blood counts will be low and will require support with antibiotics, red cell
           transfusions and platelet transfusions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1995</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the toxicity and maximum tolerated dose of 9-AC administered as a 72 hour infusion in patients with relapsed/refractory leukemia.</measure>
    <time_frame>Years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To analyze the pharmacokinetics in these patients.</measure>
    <time_frame>years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Leukemia, Myelocytic, Acute</condition>
  <condition>Acute Lymphocytic Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>9-Aminocamptothecin (9-AC)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older

          -  AML or ALL in first or subsequent relapse, secondary AML, or CML in blastic phase

          -  Central venous access

          -  ECOG performance status of less than or equal to 2

          -  Bilirubin &lt; 1.3

          -  SGOT &lt; 2 x ULN

          -  Alkaline phosphatase &lt; 2 x ULN

          -  Creatinine &lt; 1.5

        Exclusion Criteria:

          -  Undergone bone marrow transplantation

          -  Uncontrolled infection

          -  Other active malignancy

          -  HIV positivity

          -  Serious medical or psychiatric illness

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Stone, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hosptial</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2005</study_first_submitted>
  <study_first_submitted_qc>November 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2005</study_first_posted>
  <last_update_submitted>March 9, 2011</last_update_submitted>
  <last_update_submitted_qc>March 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2011</last_update_posted>
  <keyword>leukemia</keyword>
  <keyword>9-Aminocamptothecin</keyword>
  <keyword>AML</keyword>
  <keyword>ALL</keyword>
  <keyword>refractory leukemia</keyword>
  <keyword>relapsed leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>9-aminocamptothecin</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

